Maria Pérez-Vázquez

Dr. Maria Pérez-Vázquez

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
MPMaria Pérez-Vázquez
Maria Pérez-Vázquez
JCJosé Campos
José Campos
This review discusses the recent findings (July 2008-January 2010) on extended-spectrum [beta]-lactamase (ESBL)-producing Escherichia coli, mainly focussed on the epidemiology and clinical impact of infections owing to this pathogen. CTX-M-producing E. coli, mainly the CTX-M-15 producers, has emerged and disseminated worldwide as an important cause of both nosocomial and community-onset infections. The clonal spread of the ST131 epidemic E. coli strain is linked not only to the CTX-M-15 pandemia but also to other ESBLs types. The most commonly reported risk factors for community-onset ESBL-producing E. coli infections are contact with healthcare centres, recent use of antimicrobial agents, and presence of comorbidities. But infections owing to ESBL-producing E. coli in patients without obvious risk factors can occur, probably related to the increase of healthy carriers colonized with this pathogen. The main significant predictor of mortality caused by ESBL-producing E. coli is inadequate initial antimicrobial therapy. Alternatives of treatment of severe ESBL-producing E. coli infections included carbapenems, amikacin, tigecycline, and [beta]-lactam/[beta]-lactamase inhibitor combinations; with some of them enough clinical evidence is lacking (tigecycline, [beta]-lactam/[beta]-lactamase inhibitor combinations). For urinary tract infections, fosfomycin and nitrofurantoin could be useful. The worldwide emergence of multiresistant ESBL-producing E. coli raises key therapeutic problems; interventions addressed to their quick detection and early appropriate antibiotic treatment and prevention are urgently needed.

1 July 2006 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
CNCarmen Navarro
Carmen Navarro
ECEmilia Cercenado
Emilia Cercenado
ADAlberto Delgado-Iribarren
Alberto Delgado-Iribarren
IWIsabel Wilhelmi
Isabel Wilhelmi
JCJosé Campos
José Campos
A total of 151 Escherichia coli strains resistant to cefotaxime and ceftazidime were isolated during a prospective surveillance study. These strains were characterized by clinical, microbiological, and molecular analyses and were distributed into four clusters of 103, 11, 6, and 5 isolates, along with 25 unrelated strains. The principal cluster was isolated from urine, wound, blood, and other samples in three hospitals, eight nursing homes, and a community healthcare center. This cluster was associated with both nosocomial (65%) and community-acquired (35%) infections. Most strains were resistant to ciprofloxacin, gentamicin, tobramycin, cefepime, amoxicillin-clavulanic acid, and trimethoprim-sulfamethoxazole but were susceptible to imipenem. All isolates from the four clusters expressed the extended-spectrum β-lactamase (ESBL) CTX-M-15. This enzyme was also present in 8 (30.8%) of the 26 unrelated isolates. The other ESBLs, CTX-M-14 and CTX-M-32, were detected in five and seven cases, respectively, but they were detected in individual E. coli isolates only. In three clusters, bla CTX-M-15 alleles were linked to an IS Ecp1 -like element, while in eight strains of cluster II an IS 26 element preceded the bla CTX-M-15 allele. An additional pool of resistance genes included tetA , drfA14 or dfrA17 , sul1 or sul2 , aac(6′)Ib , and aac(3)IIb . All except one of the 27 isolates tested for genetic virulence markers harbored the same three virulence genes: iutA and fyuA (siderophores), and traT (serum survival factor). Epidemic or occasional isolates of cefotaxime- and ceftazidime-resistant E. coli can spread between distinct health facilities including hospitals, community health centers, and long-term care centers.

1 August 2009 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
KDKarol Diestra
Karol Diestra
Carlos JuanCarlos Juan
Carlos Juan
VBVerónica Bautista
Verónica Bautista
Ângela NovaisÂngela Novais
Ângela Novais
JCJosé Campos
José Campos

1 June 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
AOAdriana Ortega
Adriana Ortega
RBRosa Bartolomé
Rosa Bartolomé
GBGermán Bou
Germán Bou
CCCarmen Conejo
Carmen Conejo
JCJosé Campos
José Campos
The aim of this study was to determine the impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2013 by describing the prevalence, dissemination, and geographic distribution of CPE clones, and their population structure and antibiotic susceptibility. From February 2013 to May 2013, 83 hospitals (about 40,000 hospital beds) prospectively collected nonduplicate Enterobacteriaceae using the screening cutoff recommended by EUCAST. Carbapenemase characterization was performed by phenotypic methods and confirmed by PCR and sequencing. Multilocus sequencing types (MLST) were determined for Klebsiella pneumoniae and Escherichia coli . A total of 702 Enterobacteriaceae isolates met the inclusion criteria; 379 (54%) were CPE. OXA-48 (71.5%) and VIM-1 (25.3%) were the most frequent carbapenemases, and K. pneumoniae (74.4%), Enterobacter cloacae (10.3%), and E. coli (8.4%) were the species most affected. Susceptibility to colistin, amikacin, and meropenem was 95.5%, 81.3%, and 74.7%, respectively. The most prevalent sequence types (STs) were ST11 and ST405 for K. pneumoniae and ST131 for E. coli . Forty-five (54.1%) of the hospitals had at least one CPE case. For K. pneumoniae , ST11/OXA-48, ST15/OXA-48, ST405/OXA-48, and ST11/VIM-1 were detected in two or more Spanish provinces. ST11 isolates carried four carbapenemases (VIM-1, OXA-48, KPC-2, and OXA-245), but ST405 isolates carried OXA-48 only. A wide interregional spread of CPE in Spain was observed, mainly due to a few successful clones of OXA-48-producing K. pneumoniae (e.g., ST11 and ST405). The dissemination of OXA-48-producing E. coli is a new finding of public health concern. According to the susceptibilities determined in vitro , most of the CPE (94.5%) had three or more options for antibiotic treatment.

2 October 2012 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
JHJuan Manuel Hernández
Juan Manuel Hernández
MEMateu Espasa
Mateu Espasa
AFAna Fleites
Ana Fleites
DSDavid Sáez
David Sáez
JCJosé Campos
José Campos
To describe the molecular and population-level characterization of a selected group of OXA-48-like-producing Klebsiella pneumoniae isolates collected in Spain between January 2011 and May 2012. During the study period, 151 OXA-48-like-producing K. pneumoniae isolates were collected from 10 hospitals in six different Spanish regions. From these, a representative sample of 21 isolates that caused hospital outbreaks and single infections was selected for further in-depth analysis. Molecular epidemiology was investigated using PFGE and multilocus sequence typing (MLST). Resistance genes were characterized by PCR and sequencing. Plasmids carrying blaOXA-48-like were studied by PFGE with S1 nuclease digestion. All 21 isolates had ertapenem MICs ≥1 mg/L, but 47.6% remained susceptible to imipenem and meropenem; blaOXA-48 was identified in 19 isolates (90.5%) and the novel blaOXA-244 and blaOXA-245 genes were detected in 1 isolate each. With one exception, all isolates that contained blaOXA-48-like also contained blaCTX-M-15. PFGE typing revealed six clusters comprising isolates that belonged to MLST types ST11, ST16, ST392, ST405, ST437 and ST663, respectively. Two main clusters were identified: PFGE cluster 1 (12 isolates, belonging either to ST405 or ST663, from seven hospitals), and PFGE cluster 2 (4 ST16 isolates from two hospitals). Six of seven donor isolates conjugated successfully; blaOXA-48-like (but not blaCTX-M-15) was carried on ∼60 kb Inc L/M plasmids. Multidrug-resistant K. pneumoniae producing OXA-48-like carbapenemase are emerging as important pathogens in Spain due to intra- and inter-hospital, clonal and non-clonal dissemination.

1 December 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
DSDavid Saez
David Saez
VBVerónica Bautista
Verónica Bautista
SFSara Fernández-Romero
Sara Fernández-Romero
JHJuan Manuel Hernández-Molina
Juan Manuel Hernández-Molina
JCJosé Campos
José Campos
We report the epidemiological impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2012. Of the 237 carbapenemases detected, 163 were from the OXA-48 group, 60 were from VIM-1, 8 were from KPC-2, 5 were from IMP, and 1 was from NDM-1. Interhospital spread of carbapenemase-producing Klebsiella pneumoniae was due to a limited number of multilocus sequence types (MLST) and carbapenemase types, including ST15–VIM-1, ST11–OXA-48, ST405–OXA-48, ST101–KPC-2, and ST11–VIM-1. The number of CPE cases in Spain has increased sharply in recent years, due mainly to the emergence of OXA-48.